2023-2024

American Heart Association

cases, the funds will be received in future years. The chart provides s and device manufacturers in proportion to all sources of revenue.



Following is a schedule of corporate funding provided to the American Heart Association from pharmaceutical and biotech companies and medical device manufacturers during fiscal year 202 3-2024. The schedule reflects cash received during fiscal year 2023-2024 and revenue committed to the American Heart Association that will be received in future years.

2023- 2024 Corporate Funding Received from Pharmaceutical and Biotech Companies and Device Manufacturers		
Corporation	Total Cash Received During 2023- 2024 on Prior and Current Year Commitments (1)	2023- 2024 Commitments Receivable in the Future
Abbott	710,500	165,000
Alexion Pharmaceuticals Inc.	<u>-</u>	675,000
Alnylam Pharmaceuticals	150,000	150,000
Amgen, Inc.	3,100,000	812,500
Astellas Pharma Inc.	125,000	-

AstraZeneca